Post hoc pooled analysis of the phase 3 APeX-2 and APeX-J trials (92 patients with hereditary angioedema): berotralstat 150 mg improved AE-QoL total score vs placebo at 24 weeks (LSMD −7.4, 95% CI −14.3 to −0.6); gains persisted to week 96.
Secondary analysisn = 92
Caballero et al. Berotralstat and Health-Related Quality of Life in Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials